ketanserin has been researched along with Coronary Disease in 32 studies
Ketanserin: A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients.
ketanserin : A member of the class of quinazolines that is quinazoline-2,4(1H,3H)-dione which is substituted at position 3 by a 2-[4-(p-fluorobenzoyl)piperidin-1-yl]ethyl group.
Coronary Disease: An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To test the hypothesis that ketanserin augments coronary collateral blood flow and decreases myocardial ischemia during balloon angioplasty." | 9.09 | Intracoronary ketanserin augments coronary collateral blood flow and decreases myocardial ischemia during balloon angioplasty. ( Antoniadis, A; Kremastinos, DT; Kyriakides, ZS; Nikolaou, N; Sbarouni, E, 1999) |
| "Twenty patients requiring management of postoperative arterial hypertension following coronary artery bypass grafting (CABG) were randomly treated with either ketanserin (n = 10) or sodium nitroprusside (SNP) (n = 10)." | 9.06 | [Ketanserin versus sodium nitroprusside in the treatment of hypertension following coronary surgery. Effect on intrapulmonary right and left shunt and arterial oxygenation]. ( Lauwers, P; Möllhoff, T; Mulier, JP; Müller, E; Van Aken, H, 1989) |
| "Ketanserin is a selective serotonin2-receptor blocker and by this mechanism decreases peripheral resistance and blood pressure in hypertensives." | 5.28 | Influence of long-term treatment with ketanserin on blood pressure, pulmonary artery pressure, and cardiac output in patients with heart failure. ( Brune, S; Kreuzer, H; Schmidt, T; Tebbe, U, 1990) |
| "Accordingly, coronary thrombosis was induced in anesthetized, open-chest dogs by insertion of a copper coil into the left anterior descending coronary artery (LAD)." | 5.27 | Mediation of reocclusion by thromboxane A2 and serotonin after thrombolysis with tissue-type plasminogen activator in a canine preparation of coronary thrombosis. ( Ashton, JH; Buja, LM; Glas-Greenwalt, P; Golino, P; McNatt, J; Willerson, JT, 1988) |
| "To test the hypothesis that ketanserin augments coronary collateral blood flow and decreases myocardial ischemia during balloon angioplasty." | 5.09 | Intracoronary ketanserin augments coronary collateral blood flow and decreases myocardial ischemia during balloon angioplasty. ( Antoniadis, A; Kremastinos, DT; Kyriakides, ZS; Nikolaou, N; Sbarouni, E, 1999) |
| "Efficacy and safety of ketanserin was studied prospectively in a randomized and double-blind trial involving 221 patients treated for hypertension and/or coronary artery disease." | 5.06 | Incidence and clinical relevance of QT prolongation caused by the new selective serotonin antagonist ketanserin. Multicenter Ketanserin Research Group. ( Geibel, A; Hartung, J; Hohnloser, S; Just, H; Meinertz, T; Seiler, KU; Zehender, M, 1990) |
| "Twenty patients requiring management of postoperative arterial hypertension following coronary artery bypass grafting (CABG) were randomly treated with either ketanserin (n = 10) or sodium nitroprusside (SNP) (n = 10)." | 5.06 | [Ketanserin versus sodium nitroprusside in the treatment of hypertension following coronary surgery. Effect on intrapulmonary right and left shunt and arterial oxygenation]. ( Lauwers, P; Möllhoff, T; Mulier, JP; Müller, E; Van Aken, H, 1989) |
| " Ketanserin is a highly selective S2-serotonergic antagonist with additional alpha-adrenergic blocking activity, which has been proposed as a therapy for various cardiovascular diseases including hypertension." | 4.79 | Serotonin and serotonin antagonism in cardiovascular and non-cardiovascular disease. ( Frishman, WH; Huberfeld, S; Kumar, A; Okin, S; Shareef, B; Wang, YH, 1995) |
| "Ketanserin is a serotonin S2-receptor antagonist that inhibits the platelet activation and vasoconstriction induced by serotonin and also inhibits the mitogenic effect of serotonin on vascular smooth muscle cells." | 2.67 | Evaluation of ketanserin in the prevention of restenosis after percutaneous transluminal coronary angioplasty. A multicenter randomized double-blind placebo-controlled trial. ( Ball, SG; Decoster, O; Emanuelsson, H; Heyndrickx, GR; Klein, W; Liberman, H; Rutsch, W; Schroeder, E; Serruys, PW; Tijssen, JP, 1993) |
| "Ketanserin is a selective serotonin2-receptor blocker and by this mechanism decreases peripheral resistance and blood pressure in hypertensives." | 1.28 | Influence of long-term treatment with ketanserin on blood pressure, pulmonary artery pressure, and cardiac output in patients with heart failure. ( Brune, S; Kreuzer, H; Schmidt, T; Tebbe, U, 1990) |
| "Accordingly, coronary thrombosis was induced in anesthetized, open-chest dogs by insertion of a copper coil into the left anterior descending coronary artery (LAD)." | 1.27 | Mediation of reocclusion by thromboxane A2 and serotonin after thrombolysis with tissue-type plasminogen activator in a canine preparation of coronary thrombosis. ( Ashton, JH; Buja, LM; Glas-Greenwalt, P; Golino, P; McNatt, J; Willerson, JT, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (43.75) | 18.7374 |
| 1990's | 18 (56.25) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bush, LR | 1 |
| Campbell, WB | 3 |
| Kern, K | 1 |
| Tilton, GD | 1 |
| Apprill, P | 1 |
| Ashton, J | 3 |
| Schmitz, J | 2 |
| Buja, LM | 8 |
| Willerson, JT | 8 |
| De Caterina, R | 1 |
| Carpeggiani, C | 1 |
| L'Abbate, A | 1 |
| Frishman, WH | 1 |
| Huberfeld, S | 1 |
| Okin, S | 1 |
| Wang, YH | 1 |
| Kumar, A | 1 |
| Shareef, B | 1 |
| Golino, P | 6 |
| Piscione, F | 1 |
| Benedict, CR | 3 |
| Anderson, HV | 3 |
| Cappelli-Bigazzi, M | 1 |
| Indolfi, C | 1 |
| Condorelli, M | 1 |
| Chiariello, M | 1 |
| Tousoulis, D | 1 |
| Davies, G | 1 |
| Toutouzas, P | 1 |
| Kaumann, AJ | 1 |
| Frenken, M | 1 |
| Posival, H | 1 |
| Brown, AM | 1 |
| Yao, SK | 2 |
| Ober, JC | 1 |
| Gonenne, A | 1 |
| Clubb, FJ | 1 |
| Krishnaswami, A | 1 |
| Ferguson, JJ | 1 |
| Gorecki, M | 1 |
| Serruys, PW | 1 |
| Klein, W | 3 |
| Tijssen, JP | 1 |
| Rutsch, W | 1 |
| Heyndrickx, GR | 1 |
| Emanuelsson, H | 1 |
| Ball, SG | 1 |
| Decoster, O | 1 |
| Schroeder, E | 1 |
| Liberman, H | 1 |
| Beaughard, M | 1 |
| Brasset, M | 1 |
| John, G | 1 |
| Massingham, R | 1 |
| Kyriakides, ZS | 1 |
| Sbarouni, E | 1 |
| Nikolaou, N | 1 |
| Antoniadis, A | 1 |
| Kremastinos, DT | 1 |
| Lüscher, TF | 1 |
| Tanner, FC | 1 |
| Bühler, FR | 1 |
| McNatt, J | 4 |
| Murphree, SS | 1 |
| De Clerck, F | 1 |
| Hillis, LD | 1 |
| Lange, RA | 1 |
| Eber, B | 2 |
| Dusleag, J | 1 |
| Rotman, B | 1 |
| Költringer, P | 2 |
| Luha, O | 2 |
| Vanhoutte, PM | 1 |
| Brune, S | 2 |
| Tebbe, U | 2 |
| Kreuzer, H | 2 |
| Zehender, M | 1 |
| Meinertz, T | 1 |
| Hohnloser, S | 1 |
| Geibel, A | 1 |
| Hartung, J | 1 |
| Seiler, KU | 1 |
| Just, H | 1 |
| Lind, P | 1 |
| Schmidt, T | 1 |
| Woodman, OL | 1 |
| Saman, S | 1 |
| Thandroyen, F | 1 |
| Opie, LH | 1 |
| Schad, H | 1 |
| Heimisch, W | 1 |
| Barankay, A | 1 |
| Hesse, S | 1 |
| Mendler, N | 1 |
| Dietrich, WD | 1 |
| Busto, R | 1 |
| Ginsberg, MD | 1 |
| de Leeuw, PW | 1 |
| Eidt, JF | 2 |
| Allison, P | 2 |
| Noble, S | 2 |
| Möllhoff, T | 1 |
| Mulier, JP | 1 |
| Müller, E | 1 |
| Van Aken, H | 1 |
| Lauwers, P | 1 |
| Lambert, M | 1 |
| Janssens, M | 1 |
| Coche, E | 1 |
| Ashton, JH | 3 |
| Fitzgerald, C | 1 |
| Raheja, S | 2 |
| Taylor, A | 1 |
| Glas-Greenwalt, P | 1 |
| Ogletree, ML | 1 |
| Michel, IM | 1 |
| McNatt, JM | 1 |
| Taylor, AL | 1 |
4 reviews available for ketanserin and Coronary Disease
| Article | Year |
|---|---|
Serotonin and serotonin antagonism in cardiovascular and non-cardiovascular disease.
Topics: Animals; Cardiovascular Diseases; Cardiovascular System; Clinical Trials as Topic; Coronary Disease; | 1995 |
[Serotonin and cardiovascular diseases. Pathophysiology and significance of serotonin antagonists].
Topics: Aged; Animals; Arterial Occlusive Diseases; Blood Platelets; Cardiovascular Diseases; Cerebrovascula | 1992 |
The role of serotonin in thrombogenesis.
Topics: Animals; Blood Platelets; Calcium; Coronary Disease; Dogs; Fibrinolysis; Ketanserin; Phosphatidylino | 1990 |
Serotonin and the heart: effects of ketanserin on myocardial function, heart rate, and arrhythmias.
Topics: Action Potentials; Animals; Arrhythmias, Cardiac; Coronary Circulation; Coronary Disease; Heart; Hea | 1985 |
6 trials available for ketanserin and Coronary Disease
| Article | Year |
|---|---|
A double-blind, placebo-controlled study of ketanserin in patients with Prinzmetal's angina. Evidence against a role for serotonin in the genesis of coronary vasospasm.
Topics: Aged; Angina Pectoris, Variant; Coronary Disease; Coronary Vasospasm; Double-Blind Method; Drug Eval | 1984 |
Evaluation of ketanserin in the prevention of restenosis after percutaneous transluminal coronary angioplasty. A multicenter randomized double-blind placebo-controlled trial.
Topics: Adult; Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Disease; Double-Blind Method; | 1993 |
Intracoronary ketanserin augments coronary collateral blood flow and decreases myocardial ischemia during balloon angioplasty.
Topics: Angioplasty, Balloon; Antihypertensive Agents; Collateral Circulation; Coronary Circulation; Coronar | 1999 |
Ketanserin prevents early restenosis following percutaneous transluminal coronary angioplasty.
Topics: Adenosine Diphosphate; Adult; Aged; Angiography; Angioplasty, Balloon, Coronary; Coronary Disease; D | 1990 |
Incidence and clinical relevance of QT prolongation caused by the new selective serotonin antagonist ketanserin. Multicenter Ketanserin Research Group.
Topics: Aged; Arrhythmias, Cardiac; Coronary Disease; Double-Blind Method; Electrocardiography; Female; Hemo | 1990 |
[Ketanserin versus sodium nitroprusside in the treatment of hypertension following coronary surgery. Effect on intrapulmonary right and left shunt and arterial oxygenation].
Topics: Blood Pressure; Cardiac Output; Coronary Artery Bypass; Coronary Disease; Ferricyanides; Heart Rate; | 1989 |
22 other studies available for ketanserin and Coronary Disease
| Article | Year |
|---|---|
The effects of alpha 2-adrenergic and serotonergic receptor antagonists on cyclic blood flow alterations in stenosed canine coronary arteries.
Topics: Adenosine Diphosphate; Animals; Blood Flow Velocity; Coronary Circulation; Coronary Disease; Dogs; F | 1984 |
Local effect of serotonin released during coronary angioplasty.
Topics: Angioplasty, Balloon, Coronary; Coronary Disease; Coronary Vessels; Female; Humans; Ketanserin; Male | 1994 |
Intracoronary ketanserin after coronary angioplasty.
Topics: Angioplasty, Balloon, Coronary; Coronary Disease; Coronary Vessels; Humans; Ketanserin; Vasoconstric | 1994 |
Variable participation of 5-HT1-like receptors and 5-HT2 receptors in serotonin-induced contraction of human isolated coronary arteries. 5-HT1-like receptors resemble cloned 5-HT1D beta receptors.
Topics: Adult; Arteriosclerosis; Binding, Competitive; Cardiomyopathy, Dilated; Cloning, Molecular; Coronary | 1994 |
Active oxygen species play a role in mediating platelet aggregation and cyclic flow variations in severely stenosed and endothelium-injured coronary arteries.
Topics: Animals; Catalase; Coronary Circulation; Coronary Disease; Dogs; Endothelium, Vascular; Epinephrine; | 1993 |
Failure of calcium channel blockade to reduce platelet-mediated cyclic flow variations in dogs with coronary stenosis and endothelial injury.
Topics: Animals; Aspirin; Calcium Channel Blockers; Coronary Circulation; Coronary Disease; Diltiazem; Disea | 1995 |
Frequency and severity of cyclic flow alternations and platelet aggregation predict the severity of neointimal proliferation following experimental coronary stenosis and endothelial injury.
Topics: Animals; Blood Pressure; Cell Division; Coronary Disease; Coronary Vessels; Dogs; Endothelium, Vascu | 1991 |
Serotonin and acute ischemic heart disease.
Topics: Coronary Disease; Coronary Vessels; Humans; Ketanserin; Platelet Aggregation; Serotonin; Vasoconstri | 1991 |
Serotonin antagonism in the treatment of cardiac insufficiency.
Topics: Administration, Oral; Coronary Disease; Drug Evaluation; Hemodynamics; Humans; Injections, Intraveno | 1990 |
[A 58-year-old woman with unstable angina pectoris and restenosis after PTCA: successful therapy with ketanserin].
Topics: Angina, Unstable; Angiography; Angioplasty, Balloon, Coronary; Coronary Artery Bypass; Coronary Dise | 1990 |
Influence of long-term treatment with ketanserin on blood pressure, pulmonary artery pressure, and cardiac output in patients with heart failure.
Topics: Aged; Blood Pressure; Cardiac Output; Coronary Disease; Heart Failure; Heart Rate; Humans; Ketanseri | 1990 |
Enhanced coronary vasoconstrictor responses to 5-hydroxytryptamine in the presence of a coronary artery stenosis in anaesthetized dogs.
Topics: Anesthesia; Animals; Coronary Circulation; Coronary Disease; Coronary Vessels; Dogs; Electrocardiogr | 1990 |
Prevention of atherosclerotic complications with ketanserin.
Topics: Arteriosclerosis; Coronary Disease; Humans; Ketanserin; Research Design | 1989 |
Effects of the serotonin-antagonist ketanserin on the function of ischaemic and normally perfused myocardium and modification by beta-1-blockade in anaesthetized normotensive dogs.
Topics: Animals; Blood Pressure; Coronary Disease; Dogs; Heart; Heart Rate; Ketanserin; Metoprolol; Myocardi | 1989 |
Effect of the serotonin antagonist ketanserin on the hemodynamic and morphological consequences of thrombotic infarction.
Topics: Animals; Antipyrine; Autoradiography; Carbon Radioisotopes; Cerebral Infarction; Cerebrovascular Cir | 1989 |
Can atherosclerotic complications be prevented?
Topics: Arteriosclerosis; Coronary Disease; Humans; Hyperlipidemias; Hypertension; Ketanserin | 1989 |
Thrombin is an important mediator of platelet aggregation in stenosed canine coronary arteries with endothelial injury.
Topics: Animals; Antithrombin III; Arginine; Bridged Bicyclo Compounds, Heterocyclic; Coronary Circulation; | 1989 |
Ketanserin in congestive heart failure.
Topics: Aged; Cardiomyopathy, Dilated; Coronary Disease; Hemodynamics; Humans; Ketanserin; Male; Middle Aged | 1989 |
Serotonin as a mediator of cyclic flow variations in stenosed canine coronary arteries.
Topics: Animals; Coronary Circulation; Coronary Disease; Coronary Vessels; Dogs; Hemodynamics; Ketanserin; M | 1986 |
Mediation of reocclusion by thromboxane A2 and serotonin after thrombolysis with tissue-type plasminogen activator in a canine preparation of coronary thrombosis.
Topics: Animals; Blood Platelets; Bridged Bicyclo Compounds, Heterocyclic; Coronary Circulation; Coronary Di | 1988 |
Thrombin is an important mediator of cyclic coronary blood flow variations due to platelet aggregation in stenosed canine coronary arteries.
Topics: Animals; Antithrombins; Arginine; Bridged Bicyclo Compounds, Heterocyclic; Coronary Circulation; Cor | 1988 |
Cooperative mediation by serotonin S2 and thromboxane A2/prostaglandin H2 receptor activation of cyclic flow variations in dogs with severe coronary artery stenoses.
Topics: Animals; Coronary Circulation; Coronary Disease; Dogs; Drug Antagonism; Epinephrine; Hemodynamics; I | 1987 |